Search

Your search keyword '"T. Nesheiwat"' showing total 11 results
Start Over Author "T. Nesheiwat" Language undetermined
11 results on '"T. Nesheiwat"'

1. P958: REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSES FROM THE LOCOMMOTION STUDY

Author

H. Einsele, P. Moreau, V. De Stefano, D. Dytfeld, E. Angelucci, R. Benjamin, H. Goldschmidt, N. W. van de Donk, B. Besemer, C. Scheid, R. Vij, E. I. ’. Groen-Damen, M. Semerjian, V. Strulev, J. M. Schecter, T. Roccia, T. Nesheiwat, R. Wapenaar, K. Weisel, and M.-V. Mateos more...

Subjects
Hematology
Published
2022
Full Text
View/download PDF

2. S185: CARTITUDE-2 COHORT B: UPDATED CLINICAL DATA AND BIOLOGICAL CORRELATIVE ANALYSES OF CILTACABTAGENE AUTOLEUCEL IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY

Author

M. E. Agha, N. W. van de Donk, A. D. Cohen, Y. C. Cohen, S. Anguille, T. Kerre, W. Roeloffzen, J. M. Schecter, K. C. De Braganca, H. Varsos, P. Mistry, T. Roccia, E. Zudaire, C. Corsale, M. Akram, D. Geng, T Nesheiwat, L. Pacaud, P. Sonneveld, and S. Zweegman more...

Subjects
Hematology
Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results

3. P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE-1 AND LOCOMMOTION COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA

Author

K. Weisel, M.-V. Mateos, L. Vincent, T. Martin, J. G. Berdeja, A. Jakubowiak, S. Jagannath, Y. Lin, P. Thilakarathne, F. Ghilotti, J. Diels, B. Haefliger, C. Hague, A. Gonzalez, J. M. Schecter, K. S. Gries, V. Strulev, T. Nesheiwat, L. Pacaud, H. Einsele, and P. Moreau more...

Subjects
Hematology
Published
2022
Full Text
View/download PDF

4. P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA

Author

J. Hillengass, A. D. Cohen, M. Delforge, H. Einsele, H. Goldschmidt, K. Weisel, M.-S. Raab, C. Scheid, J. M. Schecter, K. C. De Braganca, H. Varsos, T.-M. Yeh, P. Mistry, T. Roccia, C. Corsale, M. Akram, L. Pacaud, T. Nesheiwat, M. Agha, and Y. C. Cohen more...

Subjects
Hematology
Published
2022
Full Text
View/download PDF

5. P960: HEALTH-RELATED QUALITY OF LIFE IN THE LOCOMMOTION STUDY OF REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Author

M. Delforge, P. Moreau, H. Einsele, V. De Stefano, J. Lindsey-Hill, L. Vincent, S. Mangiacavalli, A. Perrot, E. Ocio, S. ten Seldam, E. I. ’. Groen-Damen, M. Semerjian, V. Strulev, J. M. Schecter, T. Roccia, K. S. Gries, T. Nesheiwat, R. Wapenaar, M.-V. Mateos, and K. Weisel more...

Subjects
Hematology
Published
2022
Full Text
View/download PDF

6. B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS

Author

NWCJ van de Donk, M Delforge, M Agha, AD Cohen, YC Cohen, J Hillengass, S Anguille, T Kerre, W Roeloffzen, JM Schecter, KC De Braganca, H Varsos, L Wang, M Vogel, E Zudaire, C Corsale, M Akram, D Geng, T Nesheiwat, L Pacaud, P Sonneveld, and S Zweegman more...

Subjects
Hematology
Published
2022
Full Text
View/download PDF

7. P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY

Author

H Einsele, AD Cohen, M Delforge, J Hillengass, H Goldschmidt, K Weisel, M-S Raab, C Scheid, JM Schecter, KC De Braganca, H Varsos, T-M Yeh, L Wang, M Vogel, C Corsale, M Akram, L Pacaud, T Nesheiwat, M Agha, and YC Cohen more...

Subjects
Hematology
Published
2022
Full Text
View/download PDF

8. B05: RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Author

F Gay, JG Berdeja, V De Stefano, P Hari, B Hooper, A Haltner, S Kumar, T Martin, M-V Mateos, P Moreau, E Rosta, IA Samjoo, SZ Usmani, K Weisel, CC Jackson, Y Olyslager, JM Schecter, M Vogel, A Garrett, S Lee, T Nesheiwat, L Pacaud, C Zhou, S Valluri, LJ Costa, and Y Lin more...

Subjects
Hematology
Published
2022
Full Text
View/download PDF

9. Ti and NiPt/Ti liner silicide contacts for advanced technologies

Author

Praneet Adusumilli, B. Zhang, Chanro Park, B. Liu, Jin Cai, Balasubramanian S. Pranatharthi Haran, J. J. An, D. Ferrer, E. Engbrecht, Ahmet S. Ozcan, Hiroaki Niimi, R. Divakaruni, Y. Yan, R. Bolam, Huiming Bu, F. Chafik, Bruce B. Doris, S. Stiffler, Dechao Guo, B. Morgenfeld, Henry K. Utomo, Nicolas Loubet, N. Zhan, D. Hilscher, Jeffrey C. Shearer, W. Henson, C. Tran, C-H. Lin, James Chingwei Li, M. Oh, Hemanth Jagannathan, Jody A. Fronheiser, D. Kang, Ruilong Xie, T. Nesheiwat, Zuoguang Liu, Ravikumar Ramachandran, S. Allen, Walter Kleemeier, Oleg Gluschenkov, J. Rice, R. Lallement, Christian Lavoie, Jiseok Kim, Nicolas Breil, Siyuranga O. Koswatta, Emre Alptekin, C. Goldberg, Noah Zamdmer, Shogo Mochizuki, Veeraraghavan S. Basker, Gen Tsutsui, Keith Kwong Hon Wong, S. Fan, N. Makela, S. Jain, James J. Demarest, Christopher D. Sheraw, C.-C. Yeh, Mark Raymond, Anil Kumar, Yoo-Mi Lee, Vamsi Paruchuri, V. Sardesai, Vimal Kamineni, Woo-Hyeong Lee, Y. Ke, M. Yu, Andre Labonte, Tenko Yamashita, C. Niu, and S. Narasimha more...

Subjects
010302 applied physics, Materials science, Dopant, business.industry, 02 engineering and technology, 021001 nanoscience & nanotechnology, Epitaxy, 01 natural sciences, chemistry.chemical_compound, chemistry, 0103 physical sciences, Silicide, Electronic engineering, Optoelectronics, Node (circuits), 0210 nano-technology, business
Abstract

We discuss the transition to Ti based silicides for source-drain (SD) contacts for 3D FinFET devices starting from the 14nm node & beyond. Reductions in n-FET & p-FET contact resistances are reported with the optimization of metallization process & dopant concentrations. The optimization of SiGe epitaxy and addition of a thin interfacial NiPt(10%) are found to significantly improve p-FET contact performance. more...

Published
2016
Full Text
View/download PDF

10. BiCMOS technology improvements for microwave application

Author

Angel Rodríguez, T. Nesheiwat, N. Zhang, F. Neuilly, Francis Zaato, E. Hijzen, J. Melai, HongJiang Sun, and W.D. van Noort

Subjects
Materials science, METIS-255443, business.industry, Heterojunction bipolar transistor, Electrical engineering, BiCMOS, Cutoff frequency, Silicon-germanium, law.invention, chemistry.chemical_compound, Capacitor, EWI-14875, chemistry, law, SC-RID: Radiation Imaging detectors, IR-65297, Radio frequency, business, Electrical impedance, Microwave
Abstract

The third generation of NXP 0.25 mum SiGe BiCMOS technology (QUBiC4Xi) is presented. The NPN has fT/fmax of 216/177 GHz and BVcb0 of 5.2 V. The high-voltage NPN has 12 V BVcb0, and fT/fmax of 80/162 GHz. This is complemented with an improved MIM capacitor with 1THz cutoff frequency and new on-chip isolation structures that demonstrate a record |S12| of -60 dB at 10 GHz. more...

Published
2008
Full Text
View/download PDF

11. A phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors

Author

Lee S. Rosen, Jonathan W. Goldman, Adil Daud, G. Kato, Pamela N. Munster, Gregory M. Springett, T. Nesheiwat, Randi Isaacs, Jonathan R. Strosberg, and David S. Mendelson

Subjects
Cancer Research, DNA synthesis, business.industry, Pharmacology, DNA Damage Repair, Gemcitabine, Oncology, Tolerability, Apoptosis, Toxicity, Dose escalation, Medicine, CHEK1, business, medicine.drug
Abstract

3064 Background: In cells undergoing DNA synthesis,antimetabolite-induced replication arrest results in the induction of CHK1, halting the progression of cells through G1/S to allow for DNA damage repair. Inhibition of CHK1 by SCH 900776 is hypothesized to synergize with Gem to promote replication fork collapse and apoptosis, even in the setting of anti-metabolite resistance. Methods: A dose escalation study of SCH 900776 alone and in combination with fixed doses of Gem was conducted in subjects with advanced solid tumors. Subjects were assessed for safety, tolerability, dose-limiting toxicity (DLT), and maximal administered dose (MAD). A recommended phase II dose (RP2D) was determined based on the safety profile at pharmacologically active exposures. Results: Twenty-six subjects have been enrolled and treated with 10 (n=3), 20 (n=3), 40 (n=7), 80 (n=6), and 112 mg/m2 (n=7) of SCH 900776 administered alone and following Gem (800 mg/m2) on days 1 and 8 every 21 days. No SAEs or DLTs have been observed duri... more...

Published
2010
Full Text
View/download PDF